Evidence map›Paper›PMID 34360855›Full record

ArticleInternational journal of molecular sciences2021

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.

Katja Seipel, Carolyn Graber, Laura Flückiger, Ulrike Bacher, Thomas Pabst

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Katja SeipelDepartment for Biomedical Research, University of Bern, 2008 Bern, Switzerland.ORCID 0000-0003-3128-1573
Carolyn GraberDepartment for Biomedical Research, University of Bern, 2008 Bern, Switzerland.ORCID 0000-0002-2936-4129
Laura FlückigerDepartment for Biomedical Research, University of Bern, 2008 Bern, Switzerland.
Ulrike BacherDepartment of Hematology, University Hospital Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8771-947X
Thomas PabstDepartment of Medical Oncology, University Hospital Bern, 3010 Bern, Switzerland.
University of Bern · CHUniversity Hospital of Bern · CH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung #310030_127509
6 · The paper itself

Abstract

The FMS-like tyrosine kinase 3 (

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDioxygenasesDNA-Binding Proteinsfms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteProto-Oncogene ProteinsPyrimidinesSTAT5 Transcription FactorThiophenesTumor Suppressor ProteinsDioxygenasesDNA-Binding ProteinsFLT3 protein, humanfms-Like Tyrosine Kinase 3Proto-Oncogene ProteinsPyrimidinesS63845STAT5A protein, humanSTAT5 Transcription FactorTET2 protein, humanThiophenesTumor Suppressor Proteinsacute myeloid leukemia (AML)FMS-like tyrosine kinase 3 (FLT3)hematological malignanciesmyeloid leukemia cell differentiation protein (MCL1)signal transducer and activator of transcription 5 (STAT5)ten-eleven translocation-2 (TET2)tumor suppressor p53 (TP53)

Identifiers

PMID34360855
PMCPMC8347059
OpenAlexW3184195265

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.